ValiRx and StingRay Bio collaborate on preclinical cancer therapeutics research
ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio Limited to evaluate a series of drug candidates for cancer therapy. The collaboration focuses on an innovative series of molecules developed by StingRay, designed to target kinases linked to cancer. Innovative Approach in Oncology Drug Development Under […]